AliveCor K1000

Purpose-Built ECG Technology Driving Clinical and Commercial Success

K1000 transforms cardiac monitoring, turning a routine medical requirement into a decisive strategic advantage for organizations across life sciences and healthcare.

Built on the world's first portable, FDA-cleared, 6-lead ECG technology, K1000 leads the way in the evolving digital health technology (DHT) landscape––delivering accuracy, compliance, and a suite of new benefits from protocol to post-marketing.

Download Fact Sheet

AI-Powered Data Delivery

Powered by AI, K1000 instantly detects seven of the most common heart rhythms and provides InstantQT®, which displays QT interval measurement in seconds*

Capture Data Anytime, Anywhere

Portable, FDA-cleared, 6-lead ECG device captures accurate data in-clinic and remotely

Seamless Integration for Comprehensive Analysis

Clinicians can assess over 20 additional heart rhythms for complete cardiac safety profile

Patient-Centric Design

Noninvasive, portable, self-administered design prioritizes patient comfort while delivering medical-grade accuracy

* QT measurements made using the EK12 ECG algorithm

Real-Time Data for Decentralized and Hybrid Trials
Seamless Data Integration for Analysis
Patient-Focused for Adherence and Retention

Self-administered, medical-grade cardiac safety monitoring with K1000 enables both onsite and remote flexibility. It further transforms how cardiac data is captured and analyzed, providing the compliance, adaptability, and actionable insights required for success in any trial design.

In addition to instantly displaying QT interval measurement, seven key determinations are displayed in just 30 seconds—anytime, anywhere:

Atrial Fibrillation (AFib)
Bradycardia
Tachycardia
Normal Sinus Rhythm
Sinus Rhythm with PVCs
Sinus Rhythm with SVE
Sinus Rhythm with Wide QRS

Experience the AliveCor Impact

Connect with us to learn how you can incorporate AliveCor K1000 in your custom integration strategy and set your research apart.

Benefits Across the Entire Lifecycle

Improved Adherence and Retention

Enhanced Patient Experience

Streamlined Data Integration

Instantly Capture Quality Data

Flexible Deployment for Global Access

More Informed Decision-Making

Minimized Delays

Increased Therapy Adoption

Leading the Transformation in ECG Technology

K1000 builds on AliveCor’s legacy of innovation. The technology and expertise invested in K1000 demonstrate AliveCor’s commitment to advancing cardiac monitoring across research, clinical practice, and post-approval settings.

Built on the clinically validated KardiaMobile® 6L technology, the K1000 solution includes award-winning digital health technology, advanced AI algorithms, and a deep understanding of real-world clinical needs.

Validated and Trusted Globally

300M+

ECGs Recorded Worldwide

200+

Clinical Publications

5M+

Users Worldwide

Dive Deeper

QT Monitoring Impacts More Than Just Cardiac Health

Beyond its traditional focus on cardiac-specific therapies, every investigational drug can potentially impact cardiac function. What if we expanded QT monitoring across various therapeutic areas?

JAMA Study Shows a 6-Lead Device Could Reduce the Need to Perform a 12-Lead ECG In Resource Limited Settings

At a QTc interval threshold of 500 milliseconds, the 6-lead device had a high negative predictive value of 99.8% and was an effective triage test. This validation is pivotal for sponsors aiming to deliver quality data while alleviating common cardiac monitoring challenges.

Why Portable 6-Lead Devices Are the Future of Cardiac Monitoring in Clinical Trials

QT determinations are essential in clinical trials, but collecting them is challenging. Discover how the 6-lead device alleviates these challenges for more flexible and patient-centric trials.